在帕金森病中L-Dopa诱导的运动障碍的分子和细胞决定因素
Federica Servillo1, Maria De Carluccio1,2, Giulia Di Lazzaro3
1Neurologia, Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
NPJ Parkinson's disease
|November 30, 2024
概括
用L-Dopa治疗的帕金森病患者通常会患上L-Dopa诱导的动力障碍 (LID). 这项研究确定了条状多巴胺缩,而不是α-synuclein,是帕金森病中LID的主要原因.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- L-3,4-dihydroxyphenylalanine (L-Dopa) 治疗是帕金森病 (PD) 的标准治疗方法,但L-Dopa诱导的动力障碍 (LID) 是一个常见的并发症.
- 了解LID机制对于改善PD患者护理和运动功能管理至关重要.
研究的目的:
- 确定帕金森病 (PD) 中L-Dopa诱导的动力障碍 (LID) 的主要因果因素.
- 为了研究状多巴胺缩和α-synuclein聚合物在LID病变发生中的作用.
主要方法:
- 采用了翻译研究方法,整合了来自四种不同的PD动物模型的数据.
- 纳入了大量的人类PD患者队列,以验证临床前模型的发现.
主要成果:
- 状多巴胺缺血被确定为驱动LID发展的主要因素.
- 阿尔法-同核素聚合物似乎在LID的出现中没有发挥显著作用.
- 证据表明,不适应的基底质可塑性是LID背后的核心病理生理机制.
结论:
- 状多巴胺缩是帕金森病中L-Dopa诱导的动力障碍的关键决定因素.
- 不适应的基底质可塑性是与LID相关的运动异常的基础.
- 对于LID的未来治疗策略应该集中在解决多巴胺缩和基底腺功能障碍上.
相关概念视频
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
259
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
259
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K


